| [1] |
Chen Z, Jiang J, Fan Y, et al. Pulmonary adenoid cystic carcinoma: molecular characteristics and literature review[J]. Diagn Pathol, 2023, 18(1): 65. DOI: 10.1186/s13000-023-01354-4.
pmid: 37198615
|
| [2] |
Ran J, Qu G, Chen X, et al. Clinical features, treatment and outcomes in patients with tracheal adenoid cystic carcinoma: a systematic literature review[J]. Radiat Oncol, 2021, 16(1): 38. DOI: 10.1186/s13014-021-01770-0.
pmid: 33608038
|
| [3] |
Mendes MA, Barroso A, Campainha S. EGFR-variant adenoid cystic carcinoma of the lung[J]. J Thorac Oncol, 2018, 13(9): e178-e181. DOI: 10.1016/j.jtho.2018.04.019.
|
| [4] |
Vos JL, Burman B, Jain S, et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial[J]. Nat Med, 2023, 29(12): 3077-3089. DOI: 10.1038/s41591-023-02518-x.
pmid: 37620627
|
| [5] |
Yang Y, Ran J, Wang Y, et al. Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: a retrospective study of 133 cases[J]. Lung Cancer, 2021, 157: 116-123. DOI: 10.1016/j.lungcan.2021.05.006.
pmid: 34020823
|
| [6] |
贺嘉慧, 胡钦勇. 放疗联合特瑞普利单抗和GM-CSF治疗鼻腔鼻窦腺样囊性癌1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 442-444. DOI: 10.3760/cma.j.cn371439-20230208-00085.
|
| [7] |
Ray SK, Mukherjee S. Altering landscape of cancer vaccines: unique platforms, research on therapeutic applications and recent patents[J]. Recent Pat Anticancer Drug Discov, 2022, 18(2): 133-146. DOI: 10.2174/1574892817666220414110335.
|
| [8] |
Xie N, Shen G, Gao W, et al. Neoantigens: promising targets for cancer therapy[J]. Signal Transduct Target Ther, 2023, 8(1): 9. DOI: 10.1038/s41392-022-01270-x.
|
| [9] |
Guo Y, Lei K, Tang L. Neoantigen vaccine delivery for personalized anticancer immunotherapy[J]. Front Immunol, 2018, 9: 1499. DOI: 10.3389/fimmu.2018.01499.
pmid: 30013560
|
| [10] |
Peng M, Mo Y, Wang Y, et al. Neoantigen vaccine: an emerging tumor immunotherapy[J]. Mol Cancer, 2019, 18(1): 128. DOI: 10.1186/s12943-019-1055-6.
pmid: 31443694
|
| [11] |
Wei X, Chen F, Xin K, et al. Cancer-testis antigen peptide vaccine for cancer immunotherapy: progress and prospects[J]. Transl Oncol, 2019, 12(5): 733-738. DOI: 10.1016/j.tranon.2019.02.008.
pmid: 30877975
|
| [12] |
Habanjar O, Bingula R, Decombat C, et al. Crosstalk of inflammatory cytokines within the breast tumor microenvironment[J]. Int J Mol Sci, 2023, 24(4): 4002. DOI: 10.3390/ijms24044002.
|
| [13] |
St Paul M, Ohashi PS. The roles of CD8+ T cell subsets in antitumor immunity[J]. Trends Cell Biol, 2020, 30(9): 695-704. DOI: 10.1016/j.tcb.2020.06.003.
|
| [14] |
Djenidi F, Adam J, Goubar A, et al. CD8+ CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients[J]. J Immunol, 2015, 194(7): 3475-3486. DOI: 10.4049/jimmunol.1402711.
pmid: 25725111
|
| [15] |
Moesta AK, Li XY, Smyth MJ. Targeting CD39 in cancer[J]. Nat Rev Immunol, 2020, 20(12): 739-755. DOI: 10.1038/s41577-020-0376-4.
|
| [16] |
Chen M, Bie L, Ying J. Cancer cell-intrinsic PD-1: its role in malignant progression and immunotherapy[J]. Biomed Pharmacother, 2023, 167: 115514. DOI: 10.1016/j.biopha.2023.115514.
|
